Vertical: CFnBBase Year: 201912 Sections
Market Size (2019)
—
Projected (2027)
—
CAGR (2018–2027)
N/A
Key Players
10+
This report covers Proteases Market with forecasts from 2018 to 2027. 10 key companies are profiled.
Proteases Market is a key focus area for market intelligence and strategic research.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansAnalysis of Proteases Market from 2018 to 2027. Covers North America, Europe, Asia Pacific, Rest of the World.
Subscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansSubscribe to Wantstats
Unlock premium reports, insights, blogs, charts and more.
View Subscription PlansThe research starts with the extensive procurement process of data/information and statistics from company annual reports, government websites, statistics agencies, and paid databases. This information creates a base for the study. The information also helps to define the scope and to narrow down the area for study for the market. This raw information is processed and analyzed to extract crisp data points which currently affect or are likely to affect the industry during the forecast period. After analyzing the information, a proprietary statistical tool is used for market estimation and forecast, which generates the quantitative figures/sizes of the market/sub-segments in the current scenario as well as for the forecast period.
After estimating the market sizes and estimates, the numbers are verified with industry participants and key opinion leaders. The wide network of industry participants add value to the research and verify the numbers and estimates provided in the study. At the last stage of the research process, a final report is prepared, which is then published on different websites as well as distributed through various channels. The below figure contains the different stages of the research process to produce the report.
Data Mining
Data mining is an extensive part of our research process. It involves the procurement of market data and related information from different verified and credible sources. This step helps to obtain raw information about the components of the industry and their source, the monetary process for different end uses, the pool of market participants, and the nature of the industry and scope of the study. The data mining stage comprises both primary and secondary sources of information.
Secondary Research
In the secondary research process, various sources are used to identify and gather industry trends and information for the research process. We at Wantstats have access to some of the most diversified and extensive paid databases, which give us the most accurate data/ information on markets sizes, components, and pricing. Mentioned below is a detailed list of Sources that have been used for this study. Please note that this list is not limited to the names as mentioned; we also access other data Sources depending on the need.
Primary Research
In the primary research process, in-depth primary interviews are conducted with the CXOs to understand the market share, customer base, pricing strategies, channel partners, and other necessary information. Besides, in-depth primary interviews are conducted with the CXOs of vendors, channel partners, and others to validate the supply-side information. In addition, various key industry participants from both the supply and demand side are interviewed to obtain qualitative and quantitative information on the market. In-depth interviews with key primary respondents, including industry professionals, subject matter experts (SMEs), industry consultants, and C-level executives of major companies, are conducted to obtain critical qualitative and quantitative information pertaining to the market, as well as to assess the prospects for market growth during the forecast period. Detailed information on these primary respondents is mentioned below.
Breakdown of Primary Respondents
Forecasting Techniques
We at Wantstats follow an extensive process for arriving at market estimations, which involves the use of multiple forecasting techniques as mentioned below.
Research Methodology for Market size estimation
Understanding the market in terms of valuation is a crucial task. This becomes significantly important while investing in and choosing the correct business opportunities. In this regard, we at Wantstats undertake two market sizing approaches simultaneously, namely, the top-down and bottom-up approaches. In this step, we assess different data points, numeric attributes, information, and industry trends to arrive at the estimates and forecast values for the coming years. We use different mathematical models to estimate the market sizes of different economies and segments, each of which is further summed up to define the total market.
We at Wantstats employ a proprietary statistical tool for market estimations, which helps us to arrive at market size estimates and forecasts for different markets and industries.
Bottom-UP approach
In the bottom-up approach, the revenue of key companies and their shares in the market are assessed to deduce the market size. More than 25 key players operating in the Global Proteases market are studied. The segmental revenue of each player is analyzed and the size for the Global Proteases market is extracted from the segmental/product revenue with the help of secondary and primary research. The extracted size for the market is then validated with industry experts and partner consultants. This derived market size contributes to around 65%–70% of the total global market share in terms of revenue for the Global Proteases market. Using the data triangulation method, the overall global market size is estimated.
Top-Down approach
The overall market size is then used in the top-down procedure to estimate the size of the other sub-markets with the help of percentage splits of the market segments from secondary and primary research. The demand-side analysis is conducted, in which the expenditure of major industry players in each region is studied.
The countries considered in the scope of the Global Proteases market are the US, Canada, Mexico, the UK, Germany, France, Italy, Spain, China, Japan, India, Australia & New Zealand, South Africa, Egypt, Nigeria, Saudi Arabia, Qatar, the UAE, Bahrain, Kuwait, and Oman, Brazil, Argentina, Chile, and others. However, the number of countries varies according to the market. The figure below depicts the process of market estimation using independent tools employed by our analysts to arrive at the sizing of the market.
As a part of the market engineering, the both top-down and bottom-up approaches are utilized along with data triangulation models to derive and verify the market sizes and forecast over the coming years.
Data Triangulation
After arriving at the overall market sizes, the total market is divided into several segments and sub-segments. Again, the market breakdown and data triangulation procedures are implemented, wherever applicable, to complete the overall market engineering process and gather the exact statistics for all segments and sub-segments. The data is triangulated by studying various factors and trends from the demand and supply sides. Along with this, the market size is validated using the top-down and bottom-up approaches.
Validation
Validation is the most important stage of the report making process. Validation via an intricately designed feedback process helps us finalize the sizing estimates and forecast for the final collation. Extensive primary research is performed to verify the information. This includes telephonic and personal interviews, e-mails, feedback forms, questionnaires, and polling options/answers with a group of relevant industry participants. Validation helps to duly check the authenticity of the key industry trends, market dynamics, company market share, different business models, and conclusions.
Base Year
2019
Historical Period
2018 – 2018
Forecast Period
2020 – 2027
Primary Interviews
150+
Historical data (2018–2019) and forecast period (2019–2027)
Our research process spans primary interviews with industry stakeholders combined with comprehensive secondary data analysis, validated through triangulation across multiple independent sources.
See plans for professionals or small and medium businesses.
Analytical insights on Proteases Market covering market dynamics, competitive landscape, and strategic outlook.
Proteases Market represents a significant market opportunity with multiple growth drivers across regions and segments.
The scope of the global proteases study includes the market size analysis and a detailed analysis of the manufacturer’s products and strategies. The market has been segmented based on flavor, packaging type, distribution channel, and region.
Near-term growth will likely concentrate in modular bioreactor lines and closed-system media workflows that shorten validation cycles while preserving batch traceability.
Partnerships between CDMOs and instrumentation vendors should accelerate standard datasets for comparability across sites, improving forecasting models used in capacity planning.
Longer horizon, organoid and microphysiological adoption may reshape segment mix; teams that invest early in assay interoperability and cloud QC hooks are better positioned to capture upside without fragmenting their analytics stack.
Profiles of 104 companies operating in the Proteases Market market, including revenue, employee count, and market positioning where available.
Showing 104 of 104 companies
Advanced Enzyme Technologies is India's first and largest home-grown enzyme company and one of very few listed, fully integrated enzyme and probiotic producers anywhere. It researches, ferments, formulates and sells more than 68 enzymes and probiotics, packaged into over 400 proprietary products for more than 700 customers in 45+ countries. Roughly six-tenths of revenue comes from human nutrition, which covers pharmaceutical enzyme APIs such as serratiopeptidase, nutraceutical enzyme blends sold largely in the United States, probiotics and biocatalysts. The remainder comes from animal feed enzymes, food and non-food industrial bio-processing, and a specialised effervescent-dosage manufacturing business. The model yields EBITDA margins near 30%, a net-cash balance sheet and an ICRA AA- rating. The constraint is scale: FY26 revenue of ₹7,458 million is a small fraction of global leaders, growth has been uneven, and returns on equity sit near 11% because of a large idle treasury. --- **The company's own description.** In its August 2026 investor presentation the company describes itself as a research-driven business with global leadership in manufacturing enzymes and probiotics, committed to eco-safe solutions for human healthcare and nutrition, animal nutrition, baking, fruit and vegetable processing, brewing and malting, grain processing, protein modification, dairy processing, speciality applications and textile processing. Its stated aim is to replace traditionally used chemicals with enzymatic solutions. Its statutory accounts report a single business segment: the manufacturing and sale of enzymes. **Independent characterisation.** Advanced Enzymes is a specialty-ingredients fermentation company, and four separate economic engines sit beneath the single reported segment. 1. **Pharma enzyme API franchise (India-centric).** This is dominated by serratiopeptidase, an anti-inflammatory proteolytic enzyme sold to Indian formulators. It contributed ₹1,732 million, or 23% of consolidated revenue, in FY26, up from ₹1,193 million in FY25 (AR FY26). It is the largest single product dependency in the group. 2. **US nutraceutical enzyme business.** This runs through Advanced Enzymes USA and its subsidiaries (Cal-India Foods International, trading as Specialty Enzymes & Probiotics; Advanced Supplementary Technologies Corporation; Enzyme Innovation; Starya Labs). FY26 revenue was ₹2,122 million with PAT of ₹784 million, a 37% net margin (AR FY26). It is the highest-margin part of the group and the source of most of the goodwill. 3. **B2B application enzymes.** Animal feed enzymes are sold partly through 60%-owned Advanced Bio-Agro Tech. Food enzymes cover baking, brewing, starch and juice. Non-food enzymes cover textile, detergent and similar applications. 4. **Specialised manufacturing.** SciTech Specialities (51%) makes effervescent tablets and granules for third parties. **Revenue model.** Revenue is almost entirely product sales: enzyme concentrates, formulated blends, probiotic strains and finished dosage forms. No subscription or material licensing revenue is disclosed. Services are confined to contract research at evoxx technologies GmbH in Germany and testing at Starya Labs in the US, neither separately quantified. A small B2C line, the Wellfa brand housed in Advanced Nutrazyme Private Limited, recorded revenue of only ₹0.02 million in FY26 (AR FY26). **Value-chain position.** The company is integrated from strain discovery and genetic engineering, through submerged and solid-state fermentation (500 m³ capacity) and downstream recovery, to formulation, application support and regulatory dossiers. Customers are pharmaceutical formulators, nutraceutical brand owners and contract manufacturers, feed millers and integrators, food processors, API manufacturers using biocatalysts, and textile and detergent producers. FY26 revenue split evenly between India (₹3,727 million) and international markets (₹3,731 million) (AR FY26).
Tate & Lyle is a London-headquartered global speciality food and beverage ingredients and solutions company. It has changed fundamentally from the sugar refiner its name still evokes. Over 2010–2024 it sold its sugar refining business, its European and then North American bulk corn businesses (Primient), and its remaining commodity exposure. It then acquired CP Kelco from J.M. Huber in November 2024 for about US$1.8bn, which made it a leader in plant-based texturants such as pectin, gellan, xanthan and citrus fibre. The group now operates three regional segments (Americas, EMEA, Asia Pacific) and is organised around three technology platforms: sweetening (sucralose, stevia, allulose, monk fruit), mouthfeel (speciality starches, gums, pectin) and fortification (soluble fibres, prebiotics, proteins). Its value proposition is reformulation: helping food and beverage manufacturers reduce sugar, calories and fat while keeping taste and texture. FY2026 revenue was £2.0bn with adjusted EBITDA of £415m. Demand weakness has hurt recent performance, and a pending £2.7bn takeover by Ingredion now frames the investment case. --- ### What the company does Tate & Lyle formulates, manufactures and sells functional ingredients and ingredient systems to food and beverage manufacturers. Its products change a food's sweetness, texture, stability or nutritional profile. Customers include global consumer packaged goods (CPG) companies in beverages, dairy, bakery and snacks, and soups, sauces and dressings, as well as regional manufacturers and, for part of the portfolio, distributors. Following the CP Kelco integration, the company describes itself as holding leading positions in sweetening, mouthfeel and fortification. Its stated mission is to help customers meet consumer demand for healthier, more nutritious and more sustainable food and drink (FY26 Results Statement, CEO commentary). ### Company's own characterisation (paraphrased from FY2026 reporting) Since 1 April 2025, the company has run CP Kelco and legacy Tate & Lyle as one combined, solutions-focused business under a regional model. All three regional segments sell the complete portfolio. Management stresses three things: the reformulation expertise of its applications, sensory and nutrition-science teams; "solution chassis" (pre-engineered, modular ingredient systems, initially in mouthfeel); and a cross-selling opportunity created by combining Tate & Lyle's starches, sweeteners and fibres with CP Kelco's pectin and biogums (FY26 Results Statement, "Executing our strategy"). ### Business model and revenue model ### Value-chain position Tate & Lyle sits in the middle of the food value chain. Upstream are agricultural raw materials: corn, tapioca, citrus peel (for pectin and citrus fibre), seaweed (carrageenan), stevia leaf, monk fruit, sugar (as a feedstock for sucralose) and fermentation feedstocks (for gellan and xanthan). Downstream are branded food and beverage manufacturers. After the Primient sale, the company is a net buyer of some corn-derived inputs, secured under long-term supply agreements with Primient. These agreements had about 18 years remaining as of 2024 (FY24 Results Statement). ### Customer types and end-markets - **Customer types:** multinational CPG companies; regional and local food manufacturers; beverage bottlers; dairy processors; infant nutrition makers; foodservice suppliers; and distributors serving smaller customers. - **Core categories (company-defined):** beverages; dairy; soups, sauces and dressings; bakery and snacks. Infant nutrition, confectionery and some non-food uses are adjacent (CP Kelco gums also serve personal care and industrial markets). - **Geographic exposure, FY26:** Americas 49.6% of revenue (North America 39.2%, Latin America 10.4%); EMEA 31.7%; Asia Pacific 18.7% (FY26 Results Statement, Note 4). ### Independent characterisation Tate & Lyle is a mid-cap, mid-margin speciality ingredients company that only recently stopped being a commodity company. Its portfolio is strongest in texture and mouthfeel, where CP Kelco's pectin and biogums franchise has real technical barriers. It has a meaningful but structurally pressured sweetener business: sucralose faces Chinese competition and some "clean-label" customer moves away from artificial sweeteners. It also retains residual bulk sweetener and co-product exposure in Europe (£75m of FY26 revenue). The core strategic question has always been whether a sub-£2.5bn-revenue company can match the scale of the leaders: Kerry, IFF, DSM-Firmenich, Cargill, ADM and Ingredion. The board's decision to recommend the Ingredion offer in June 2026, after two years of disappointing organic growth, effectively answers that question in favour of consolidation.
Biocatalysts Ltd. is a Welsh specialty enzyme developer and manufacturer and the operating core of BRAIN Biotech AG's BRAINBiocatalysts segment. Founded in 1983, it serves niches the commodity enzyme majors under-serve: flavour and dairy protein modification, plant-based foods, baking, brewing and beverages, pet food, and custom enzymes for life science and pharmaceutical customers. Its model combines a catalogue of branded food enzymes (Promod, Lipomod, Flavorpro, Depol and others) with a fee-for-service enzyme development and manufacturing offer that takes a customer's enzyme from discovery through strain development to commercial fermentation in Cardiff. Since November 2023 it has also owned BRAIN's continental European and US enzyme blending and distribution businesses (Breatec, WeissBioTech, Biosun). The entity is small, with group turnover of GBP 36.2 million in FY2024, and its fortunes are tied to a parent that is loss-making at group level, thinly capitalised and in the middle of a CEO transition. --- **Company's own description.** The company describes itself on its website as a biotechnology company with global reach that produces specialist enzymes at commercial scale for a variety of industries, using its technical, commercial and regulatory capabilities for customers. Its boilerplate adds that it was established in 1983 and has been a member of the BRAIN Biotech Group since 2018. The description from the latest annual report could not be quoted because the filed accounts PDF was not read for this dossier. **Independent characterisation.** Biocatalysts Ltd. is a mid-tier specialty enzyme house with three revenue streams. 1. **Catalogue enzyme products.** Branded, off-the-shelf enzyme preparations, mainly proteases, lipases, carbohydrases and flavour enzymes, sold to food, beverage, flavour, nutrition and pet food manufacturers. Sales are transactional, by volume, direct and through distributors. 2. **Custom enzyme development and manufacture.** Fee-based development projects ("Flexible Work Packages" and "Custom Enzyme Development") followed by long-term supply of the resulting enzyme. This stream combines service income during development with product income after scale-up. The life science offering is marketed with the parent as "BRAINBiocatalysts Life Science Solutions" under the line "Your Product | Your IP | Your Future", meaning the customer keeps the intellectual property. 3. **Fermentation services.** Contract microbial fermentation and downstream processing, including large-scale freeze-drying, at the Cardiff site. **Revenue model mix.** The split between product, service and contract manufacturing revenue is not publicly disclosed in the sources consulted. There is no subscription or material licensing revenue at entity level. Royalty-type income sits in the parent's BRAINBioIncubator segment, not in Biocatalysts Ltd. **Value chain position.** The company is a manufacturer and formulator. It sits downstream of enzyme discovery, where it draws on BRAIN Biotech's Zwingenberg research campus and strain libraries, and upstream of food and pharmaceutical processors. Since November 2023 it has also owned blending, application and distribution businesses in the Netherlands, Germany and the United States. **Customer types and end-markets.** The website lists six sectors: Food, Flavors, Life Science, Pharmaceuticals, Industrial Biotech, and Fermentation Services. Customer names and concentration are not publicly disclosed.
Amano Enzyme is a family-led, Nagoya-based specialty enzyme manufacturer with 127 years of corporate history and 78 years of enzyme production. It does not compete in bulk commodity enzymes for detergents, biofuels or feed. Its franchise is high-value microbial enzymes for food processing, digestive health and dietary supplements, diagnostics, regenerative medicine and biocatalysis. It has three Japanese plants, a plant in Jiangsu, China, and a manufacturing and blending site in Elgin, Illinois. It combines traditional koji (solid-state) and liquid fermentation with classical strain screening and modern protein engineering. More than 70% of sales come from outside Japan. R&D spending runs at about 10% of sales, supported by roughly 420 patents and a library of about 20,000 microbial strains. The balance sheet is very strong, with an equity ratio near 89% at March 2024. Disclosure is minimal. Growth rests on plant-based protein enzymes and a 2024 push into non-food industrial applications. --- **Company's own description.** The company describes its business as the manufacture and sale of enzyme agents for the pharmaceutical, food and manufacturing industries and for diagnostic reagents, together with pharmaceuticals, veterinary medicines and feed additives (Company Overview; Sustainability Report 2025). Its recruiting materials divide activity into two fields. The medical field covers pharmaceutical, diagnostic and synthesis enzymes. The food field covers enzymes for dairy, seasonings, alcoholic beverages and baking (Mynavi). **Independent characterisation.** Amano is a pure-play specialty enzyme producer and sits mid-value-chain. It sources microbial strains from nature, improves them by classical mutagenesis or, where markets permit, by genetic and protein engineering. It then ferments, purifies, formulates and sells enzyme preparations to industrial customers. It does not sell consumer products. The company once made over-the-counter medicines such as the "Biodiastase" stomach remedy, and it exited that business when it decided in 1996 to specialise in enzymes. **Revenue model.** Revenue is almost entirely product sales of enzyme preparations, sold by weight and activity unit to business customers. The company also offers tailor-made enzyme development with customers ("Tailor-Made Solutions" and the "Enzyme Application Studio"). Whether this generates separate service or licensing revenue is not publicly disclosed. There is no evidence of subscription revenue. The product, service and licensing mix is not publicly disclosed. **Value chain position and customers.** Customers are food and beverage manufacturers, plant-protein ingredient processors, dietary supplement formulators, over-the-counter drug makers, in-vitro diagnostics manufacturers, cell-therapy and regenerative medicine developers, and fine-chemical and pharmaceutical synthesis operations. Japanese recruiting disclosures state that Amano's digestive enzymes hold the leading share in domestic stomach remedies (Mynavi; Plus-H). **End-markets.** The website organises applications under three headings: Food, Healthcare & Medical, and Green Chemistry. A separate microsite, Plants Unlimited, covers plant-based food enzymes. The Sustainability Report 2025 adds prospective fields that the company is exploring: agriculture, energy, materials, textiles and environmental conservation.
Specialty Enzymes & Biotechnologies — CFnB
Powering the world's best teams.
From next-gen startups to established enterprises.
Trusted by forward-thinking businesses
for data-driven intelligence
Co-Founder, Mojave Rail Fabrication Limited
This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job.
Manager, JavolVision
Thanks, I am so happy that we worked together. Maybe we still can work together in the future.
Sales Operations & Pricing Manager, Intel
Thanks. It's been a pleasure working with you, please use me as reference with any other Intel employees.
Sales Leader, Bamberg
We bought your "2025 report" in 2020. Everything is fine and very good.
Account and Business Manager, EFS-Holland BV
Thanks for sending the report it gives us a good global view of the Betaïne market.
Senior Retail Manager, LG Chem
We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.
Management Consultant, Level 21
I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.
Group Product Manager HVAC & Fire Protection GMA, Rockwool
I have been reading the first document or the study, the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!
R&D Director, Seojin
Thanks for your great support. Appreciate it. Well received report. It helps us to understand market well. We're planning other area of survey in the future, let's keep in touch.
Strategy & Business Development Director, Dogan Holding
We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.
Historical performance and future projections (2020–2030, USD Billion)
